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INTRODUCTION
The treatment of equine sarcoids has always been 
challenging, due to the variable clinical presentation 
of lesions and the frequent local recurrences. There-
fore, careful selection of the appropriate treatment 
for each sarcoid and each horse should be made, ta-
king into account the localization, number and size 
of the tumors, the treatment history, the financial va-
lue of the animal and the owner compliance to fulfil 
the treatment schedule (Marti et al., 1993; Carstanjen 
and Lepage, 1998). 
Both surgical and non-surgical techniques have 
been described with variable success rates. Since 
none of the current techniques has been proven to be 
100 % successful (Marti et al., 1993), the confiden-
ce of owners in conventional treatments may decre-
ase, leading them to use a whole scale of topical oint-
ments (including toothpaste), homeopathy,... Despite 
the lack of any scientific evidence, tumor regression 
can occasionally be seen after these alternative the-
rapies. Cure, however, may also be a result of spon-
taneous regression, which is observed in up to 32 % 
of the cases (Brostrom, 1995; Martens et al., 2001b). 
There fore, benign neglect can be an option, especial-
ly in case of small tumors (Knottenbelt et al., 1995; 
Pascoe and Knottenbelt, 1999). Careful monitoring 
is yet very important, since aggravation can hap-
pen anytime without an obvious reason. It should be 
kept in mind that not all horses with equine sarcoids 
can be cured: in horses with a very large number of 
sarcoids, or with sarcoids with a very large surface, 
treat ment may be impossible. Even in case of a small 
single sarcoid owners should be warned about possi-
ble local recurrence and deterioration of the sarcoid 
(Knottenbelt et al., 1995; Carstanjen and Lepage, 
1998). Moreover, the development of new sarcoids 
on other locations is always possible (Brostrom, 
1995; Carstanjen et al., 1997; Carstanjen and Lepa-
ge, 1998). It is generally accepted that the prognosis 
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treatment of sarcoids is often challenging, due to the variable clinical presentation of lesions and the 
frequent local recurrences. in this article, both the surgical and the non-surgical treatment of equine sar-
coids are reviewed. it is generally accepted that the prognosis is worse if unsuccessful attempts have been 
made previously. Therefore, the best available treatment option should always be used at the first attempt 
of treatment. different surgical approaches have been reported, including conventional excision, cryosur-
gery and cO
2
 laser surgery. success rates are high if a non-touch approach, wide surgical margins and 
general anesthesia can be applied. local chemotherapy is a valuable addition in the treatment of sarcoids 
and can be combined with surgery. radiotherapy is a very successful treatment, but safety precautions 
prevent routine application. local immunotherapy including Bacillus calmette-guérin vaccination and 
imiquimod cream are commonly applied treatments which induce rather effective tumour regression.
SAMENVATTING
 
De behandeling van sarcoïden is vaak een uitdaging door het variabel klinisch gedrag en het frequent optreden 
van lokale recidieven. In dit artikel wordt een overzicht gegeven van zowel de chirurgische als niet-chirurgische 
behandeling van equine sarcoïden. Algemeen wordt aangenomen dat de prognose slechter wordt indien een eer-
dere behandeling vruchteloos bleek. Daarom is het van belang om bij de behandeling onmiddellijk de best mo-
gelijke optie aan te wenden. Verschillende chirurgische benaderingen worden beschreven, waaronder de conven-
tionele excisie, cryochirurgie en CO
2
-laserbehandeling. Het slagingspercentage is hoog indien een “non-touch” 
benadering, de wegname van brede randen normale huid en een algemene anesthesie worden toegepast. Lokale 
chemotherapie is een waardevolle aanvulling bij de behandeling van sarcoïden en kan gecombineerd worden met 
chirurgie. Bestraling is een andere succesvolle behandeling, maar strenge veiligheidsmaatregelen belemmeren 
een routinematige toepassing ervan. Lokale immunotherapieën, zoals de vaccinatie met Bacillus Calmette-Guérin 
en imiquimod crème, worden regelmatig toegepast en resulteren in behoorlijk goede tumorregressie.
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for treatment is significantly worse if one or more 
unsuccessful attempts have been made previously 
(Knottenbelt and Walker, 1994). Therefore, the best 
available treatment option with the highest chance of 
success should always be used at the first attempt of 
treatment (Pascoe and Knottenbelt, 1999).
In this paper, only the most commonly ap plied 
treat ments in equine practice will be presented. 
Treat ments with only anecdotic evidence, such as 
Sanguinara canadensis (XXTerra®), photodynamic 
the rapy, homeopathy, acupuncture, ligation, hyper-
thermia and various topical ointments will not be dis-
cussed further (Hoffman et al., 1983; Schwierczena, 
1993; Brostrom, 1995; Thoresen, 1995; Pascoe and 




Surgical excision of equine sarcoids has been app-
lied for decades with variable success. High recurren-
ce rates of 40 to 72 % are reported (Ragland, 1970; 
Diehl et al., 1987; Mcconaghy et al., 1994; Brostrom, 
1995). This can be attributed to the infiltrative nature 
of the tumor and auto-transplantation of tumor cells 
during the surgical procedure (Klein, 1990; Howart, 
1990). On histology, fronds of tumor cells infiltrating 
the surrounding dermis and sometimes the underly-
ing tissues can be observed (Ragland, 1970; Tarwid et 
al., 1985). The detection of BPV DNA at the surgical 
margin of an excised sarcoid correlates with an incre-
ased risk of recurrence (Martens et al., 2001a). When 
the excision is performed with wide normal skin mar-
gins (at least 12 mm; Figure 1) and a non-touch ap-
proach (i.e. changing of gloves and material after tu-
mor removal and extensive flushing of the wound), 
auto-inoculation with tumor cells and viral material 
can be avoided and success rates of more than 80 % 
are achieved (Howart, 1990; Brostrom, 1995; Mar-
tens et al., 2001b). Another major factor in the prog-
nosis is the possibility to perform the excision un-
der general anesthesia (80 % success) compared to 
working on the standing horse (24 % success). Ge-
neral anesthesia provides the surgeon a clear view on 
the sarcoids, a good ability to remove wide margins 





Excision with the CO
2
 laser is an efficient tool for 
the treatment of equine sarcoids. Success rates range 
from 60 to 89 % (Diehl et al., 1987; Vingerhoets et al., 
1988; Carstanjen et al., 1997; Martens et al., 2001b). 
Large masses are commonly laser-excised using the 
same approach as described for the conventional ex-
cision. Small or flat lesions can be entirely vaporized 
with the CO
2
 laser (Diehl et al., 1987; Vingerhoets 
et al., 1988; Carstanjen et al., 1997; Weigand et al., 
1997). Laser ablation causes less damage to the sur-
rounding tissues and less spread of malignant cells to 
healthy regions compared to sharp surgical excision 
with mechanical tools (Carr, 2006). However, poor 
cosmetic results including scar tissue formation, alo-
pecia, leucotrichia and transient abnormal hair color 
can sometimes be observed (Vingerhoets et al., 1988; 
Carstanjen et al., 1997). Other drawbacks are the cost 
of the equipment and the required safety precautions 
against burns, fire, eye damage and smoke inhalation 
(Palmer, 1989).
cryosurgery
Both in human and veterinary medicine cryosur-
gery has become an accepted way of treating malig-
nancies. Cell death is obtained by repeated freeze-
thaw cycles, with optimal cryonecrosis achieved by 
rapid freezing and slow thawing of the tissue (Far-
ris et al., 1976; Fretz and Barber, 1980). Prior to free-
zing, large sarcoid masses are debulked to the level of 
the surrounding skin or even lower, followed by free-
zing of the tumor base and a normal skin margin with 
liquid nitrogen (Figure 2). Tissue should be frozen to 
at least -20 to -25 °C. Temperature control is essen-
tial and can be obtained with thermocouple needles 
(Farris et al., 1976). After the procedure, a black lea-
figure 1. demarcation of a normal skin margin of 12 mm 
to perform excision of a fibroblastic sarcoid.
figure 2. continuous circulation contact probes 
for cryosurgery of debulked sarcoid lesions. tissue 
temperature is monitored carefully with thermocouple 
needles inserted into the tumor mass.
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thery crust develops within a few days, and sloughs 
gradually over several weeks eventually leading to an 
open wound which heals by second intention.
Success rates vary from 60 to 100 % (Lane, 1977; 
Fretz and Barber, 1980; Klein et al., 1986; Diehl et 
al., 1987; Martens et al., 2001b). Occasionally, spon-
taneous regression of non-treated sarcoids on the 
same horse can be observed, indicating that destruc-
tion of one tumor can result in an immune response 
against other, distant sarcoids (Lane, 1977). Disad-
vantages of the technique are the prolonged anesthe-
sia time required, the cosmetic effects (scarring, leu-
codermia, leucotrichia) and the possible damaging of 
underlying structures. The latter makes cryosurgery 
less suitable for periocular sarcoids or tumors loca-
ted on large vessels, nerves, ligaments or joints, un-
less careful temperature control with thermocouples 
is performed (Lane, 1977; Fretz and Barber, 1980; 
Mcconaghy et al., 1994; Knottenbelt et al., 1995).
NON-SURGICAL TREATMENT
chemotherapy
Administration of cytotoxic drugs results in tumor 
cell death and can be performed in two ways: syste-
mically and locally. Local chemotherapy can be ap-
plied intralesionally or topically. The rationale for lo-
cal chemotherapy is based on achieving a high drug 
concentration over time in the tumor while sparing 
normal tissue. The general circulation is bypassed 
and a low systemic exposure is obtained, thereby mi-
nimizing toxicity (Theon, 1998). Due to its cutaneous 
localization, sarcoids are most convenient for local 
chemotherapy.
Intralesional injection of cytotoxic drugs directly 
into the tumor allows higher intratumoral drug con-
centrations and permits accurate placement of the 
drug within the tumor (Theon, 1998; Mair and Cou-
to, 2006). The beneficial effects are enhanced if drug 
carriers that prolong the persistence of the drug in the 
tumor are used. Viscous fluid preparations such as se-
same seed or almond oil are frequently used to achie-
ve this effect (Theon et al., 1993). The most widely 
used drug in this manner is cisplatin with a 2-year lo-
cal control rate of approximately 90 % (Theon et al., 
1993; Theon et al., 1994; Theon, 1998). Intralesio-
nal cisplatin can be effective as the sole treatment for 
small sarcoids, but for large tumors the combined use 
with surgery is recommended (Theon et al., 1994; 
Theon, 1998). Local cisplatin injected at the time of 
surgical sarcoid excision was shown not to have any 
adverse effect on wound healing (Theon et al., 1994). 
Emulsions are made up from 1 ml of an aqueous so-
lution of 10 mg cisplatin and 2 ml sesame oil and 
are mixed using 2 syringes and a 3-way valve (Figu-
re 3). A dose rate of 1 mg cisplatin/cm³ of tumor can 
be applied. The sarcoid as well as a margin of nor-
mal skin of 1-2 cm should be injected using a paral-
lel-row or field-block technique (Theon et al., 1997). 
A standard treatment protocol includes 4 injections at 
2-week intervals. Side effects of treatment are strict-
ly local (inflammation, swelling, focal ulceration) 
and self-limiting (Theon, 1998). Prophylactic antibi-
otic therapy and anti-inflammatory drugs are recom-
mended after each treatment session to prevent acu-
te clostridial infection. The cosmetic and functional 
results are excellent (Theon, 1998). Alternative cis-
platin formulations with almond oil or epinephrine 
as well as local chemotherapy with bleomycin and 
5-fluorouracil (5-FU) are described but appear to be 
less effective (Bouré et al., 1991; Doyle, 1998; Knot-
tenbelt and Kelly, 2000; Stewart et al., 2006). 
Topical chemotherapy has been used for over 100 
years to treat equine sarcoids. However, the effect 
of only a few of these drugs has been studied scien-
tifically. 5-FU can be applied as a cream for single, 
small occult or verrucous sarcoids but also for larger 
areas of occult or verrucous sarcoids that are not ame-
nable to any other form of treatment. Due to poor dif-
fusion and inadequate distribution from the surface 
to the deep margins, the use of 5-FU should be limi-
ted to flat lesions (Theon, 1998). Topical 5-FU needs 
to be applied daily for 30-90 days. Alternatively, it 
can be applied less frequently under a bandage (Ro-
berts, 1970). A success rate of 66 % was observed 
(Knottenbelt and Kelly, 2000). To aid the penetration 
through the epidermis, 5-FU can be mixed with 
podophylin, an irritant cathartic (Mcconaghy et al., 
1994; Piscopo, 1999). The treated area can show a 
marked inflammatory reaction, but scarring is usu-
ally minimal (Pascoe and Knottenbelt, 1999). Unli-
censed topical ointments (AW-3-LUDES and AW-4
-LUDES) containing a variety of heavy metals with 
5-FU and thiou racil can be applied on successive or 
alternate days for 3 to 5 treatments, depending on the 
size, number and nature of the sarcoids (Knottenbelt 
and Walker, 1994; Knottenbelt and Kelly, 2000). This 
treatment may cause severe local irritation and scar 
contracture but a resolution rate of 80 % has been 
reported in sarcoids being treated for the first time 
figure 3. Preparation of cisplatin emulsion by mixing 
of an aqueous cisplatin solution and sesame oil through 
a 3-way valve.
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(Knottenbelt and Walker, 1994). The success rate de-
creases by 30 to 40% for each previous unsuccessful 
treatment.
radiotherapy
Radiotherapy induces tumor destruction by ioni-
zing radiation. The most frequently used radiothe-
rapeutic method in horses is interstitial brachythe-
rapy with iridium-192 reporting one- and five-year 
progression-free survival rates of 87 and 74 % res-
pectively for non-ocular sarcoids and 98-100 % for 
periocular sarcoids (Wyn-Jones, 1983; Turrel et al., 
1985; Theon and Pascoe, 1995; Knottenbelt and Kel-
ly, 2000; Byam-Cook et al., 2006). It involves the 
implantation of sealed radioactive sources within the 
tissue to treat the tumor at short source-object dis-
tances. Because of the long half-live of iridium-192 
(74.2 days), the implants are removed once the re-
quired dose has been administered, usually after 5 to 
6 days. The primary advantage is that high radiation 
doses can be given directly into the tumor with mi-
nimal damage to the surrounding tissues (Henson 
and Dobson, 2004). The technique is very suitable 
for tumors on locations where surgical excision is not 
possible (eyelids, commissure of lips) and good re-
sults have been obtained for recurrent sarcoids. Local 
complications such as necrosis and infection and mi-
nor cosmetic defaults (leucotrichia, alopecia, mini-
mal scarring) have been observed (Turrel et al., 1985; 
Theon and Pascoe, 1995; Theon, 1998; Byam-Cook 
et al., 2006). A major drawback of this otherwise va-
luable treatment is the safety of the operators and the 
need for patient isolation (Wyn-Jones, 1979; Walker 
et al., 1991).
immunotherapy
The purpose of immunotherapy is to enhance the 
ability of the host to reject the tumor. Antitumoural 
effects are produced primarily through enhanced im-
munologic activity. Many immunostimulants have 
been evaluated in horses, including Bacillus Calmette 
-Guérin (BCG) vaccine, autovaccination and imiqui-
mod 5 % cream.
BCG is an attenuated strain of Mycobacterium 
bovis originally developed as a tuberculosis vacci-
ne in man and is currently still in use for intravesi-
cal treat ment of superficial bladder cancer (Brake et 
al., 2000). Live organisms, dead organisms and cell 
wall extracts have been used in combination with va-
rious adjuvants for intratumoral injection of equine 
sarcoids. Tumor regression involves both non-speci-
fic and specific mechanisms and is based on a de-
layed hypersensitivity reaction (Morton and Barth, 
1995). BCG vaccination consists of multiple injec-
tions into the tumor mass and tumor bed to ensure 
complete infiltration of the target volume. Most com-
monly 4 injections at a 2-3 week interval are perfor-
med. The success rate ranges from 60-100 % and 
is mainly dependent on tumor size and localization 
(Klein et al., 1986). Periocular sarcoids are most res-
ponsive to treat ment with local control rates up to 
100 %. Sarcoids on the limbs respond poorly and 
vaccination can result in massive oedema formation, 
lymphangitis or even septic arthritis (Klein et al., 
1986; Owen and Jagger, 1987; Theon, 1998). Cytore-
ductive surgery prior to treatment of bulky tumors is 
recommended (Theon, 1998). General (anaphylactic 
shock, death, fever) and local (oedema, purulent dis-
charge, ulceration) side effects have been described 
and therefore administration of non-steroidal or ste-
roidal anti-inflammatory drugs is recommended prior 
to BCG vaccination (Theon, 1998).
Autogenous vaccination of sarcoids has been per-
formed with variable success rates. Although promi-
sing results of autovaccination combined with food 
supplements have been reported (Kinnunen et al., 
1999), other authors have reported worsening of the 
condition or new sarcoid development after autovac-
cination (Knottenbelt et al., 1995; Pascoe and Knot-
tenbelt, 1999).
Imiquimod (AldaraTM) is an immune response 
modifier with potent antiviral and antitumoral acti-
vity showing promising results for the treatment of 
equine sarcoids. Successful treatment of human ano-
genital warts, actinic keratosis and superficial ba-
sal cell carcinoma has been reported (Beutner et al., 
1998; Marks et al., 2001; Salasche et al., 2002). Re-
cent studies have shown good results for the treat-
ment of equine sarcoids (Nogueira et al., 2006; own 
unpublished results). Treatment consists of applica-
tion of a thin layer of cream on the tumor surface 3 
times a week during several weeks to months. In one 
study, 60 % of the treated sarcoids resolved entirely 
and another 20 % showed more than 75 % reduction, 
most of them being recurrences after previous treat-
ment (Nogueira et al., 2006). Local side effects, such 
as ulceration, pain and depigmentation are often ob-
served.
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Onderzoek naar equine sarcoïd
Op de Vakgroep Heelkunde en Anesthesie van de Huisdieren van de Faculteit Diergeneeskunde te Merelbeke 
loopt momenteel een onderzoek naar de transmissie van het boviene papillomavirus. Hiervoor zijn we op zoek 
naar proefpaarden met equine sarcoïden, evenals naar paarden die vroeger reeds behandeld werden voor sarcoï-
den maar nu sarcoïd-vrij zijn. Deze paarden zullen gebruikt worden om de exacte manier van transmissie te ont-
rafelen, uitgaande van viraal materiaal afkomstig van zowel runderen als van paarden. Opgelet: deze paarden zul-
len worden overgekocht door de vakgroep en kunnen dus niet in het bezit blijven van de eigenaar! Indien u in uw 
cliënteel dergelijke dieren hebt die anders toch moeten geëuthanaseerd of geslacht worden, kunt u ons steeds con-
tacteren voor overname van deze dieren.
Contact: Pieter Depoorter (pieter.depoorter@UGent.be), Lies Bogaert (lies.bogaert@UGent.be)  
OPrOeP
Vita-Vitaal is een jonge, snelgroeiende organisatie, gericht op de grote veehouderijbedrijven. Wij beheren een aantal specifieke 
voedingsproducten met internationale impact. Voor onze solide, technische productondersteuning zijn wij op zoek naar een 
enthousiaste en ondernemende
Dierenarts
w e r k g e b i e d  B r a b a n t - L i m b u r g
Binnen ons team past een praktisch ingestelde (ervaren) persoonlijkheid met uitstekende communicatieve vaardigheden. 
Uw kennis is voornamelijk gericht op diergezondheidsaspecten in de varkenshouderij. Voedingskundige know how kunnen wij 
uiterst nauwgezet aanvullen, waardoor uw specialiteiten diergezondheid, voeding en zoötechniek optimaal tot hun recht komen.
Vita-Vitaal biedt de juiste kandidaat een uiterst boeiende en zelfstandige functie. U onderhoudt waardevolle contacten met 
veehouders in de intensieve veehouderij, studieclubs en collega’s. Tevens neemt u zitting in ons managementteam. 
Onze primaire en secundaire arbeidsvoorwaarden zijn solide en bijzonder goed te noemen.
Belangstellenden kunnen hun schriftelijke sollicitatie binnen 21 dagen richten aan: Vita-Vitaal, t.a.v. de heer drs. R. Fourier, 
postbus 21, 6114 ZG Susteren. U kunt ook per e-mail reageren: 
info@vita-vitaal.nl. Telefonische informatie betreffende deze vacature kunt u verkrijgen bij de heer drs. R. Fourier, 
(Managing Director and Technical Support), tel: +32 495201478.
